Kailera Therapeutics, Inc. (KLRA)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
22.94 USD
After hours: 22.94 |
Hot Take ↕ | May 25, 2026, 3:57 a.m. EDT
The stock presents a classic biotech dilemma: a massive recent catalyst versus a fundamentally broken balance sheet. On the short end, the price has stabilized near the IPO level after a volatile debut, showing no clear momentum edge to justify a bullish entry; the recent trading range suggests indecision rather than a breakout. However, the long-term outlook is severely compromised by the company's financial reality. Despite the excitement surrounding the $625 million IPO and promising obesity drug data, the business is burning cash aggressively, with operating and free cash flows deeply negative. More critically, the balance sheet shows a negative book value and negative equity, indicating that the company's assets do not cover its liabilities. This structural deficit, combined with negative returns on assets and equity, means the stock is priced on future success that is far from guaranteed. With no dividend to provide income and a capital structure that requires constant dilution or funding, the investment case relies entirely on the execution of a high-risk clinical pipeline, making it unsuitable for investors seeking stability or value. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 2,972,235,008 |
| Forward P/E | -6.15 |
| Website | https://www.kailera.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.11769229 |
| Address1 | 180 Third Avenue |
| Address2 | 4th Floor |
| All Time High | 28.23 |
| All Time Low | 19.01 |
| Ask | 29.28 |
| Ask Size | 2 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 407,150 |
| Average Daily Volume3 Month | 941,317 |
| Average Volume | 941,317 |
| Average Volume10Days | 407,150 |
| Bid | 17.34 |
| Bid Size | 2 |
| Book Value | -18,713.672 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.94 |
| Current Ratio | 12.015 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,778,803,200 |
| Day High | 24.19 |
| Day Low | 22.765 |
| Display Name | Kailera Therapeutics |
| Earnings Timestamp End | 1,786,132,800 |
| Earnings Timestamp Start | 1,786,132,800 |
| Ebitda | -158,030,000 |
| Ebitda Margins | 0.0 |
| Eps Current Year | -4.29 |
| Eps Forward | -3.73077 |
| Eps Trailing Twelve Months | -1.78 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 22.92069 |
| Fifty Day Average Change | 0.019309998 |
| Fifty Day Average Change Percent | 0.00084247015 |
| Fifty Two Week Change Percent | -11.769229 |
| Fifty Two Week High | 28.23 |
| Fifty Two Week High Change | -5.289999 |
| Fifty Two Week High Change Percent | -0.18738927 |
| Fifty Two Week Low | 19.01 |
| Fifty Two Week Low Change | 3.9300003 |
| Fifty Two Week Low Change Percent | 0.20673332 |
| Fifty Two Week Range | 19.01 - 28.23 |
| First Trade Date Milliseconds | 1,776,432,600,000 |
| Float Shares | 8,662 |
| Forward Eps | -3.73077 |
| Forward P E | -6.1488647 |
| Free Cashflow | -59,885,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 145 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.39777002 |
| Implied Shares Outstanding | 129,565,608 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-04-17 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts. |
| Long Name | Kailera Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,972,235,008 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_1899116257 |
| Net Income To Common | -148,955,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,972,235,047 |
| Number Of Analyst Opinions | 5 |
| Open | 23.0 |
| Operating Cashflow | -120,210,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 781 317 0290 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 22.94 |
| Post Market Time | 1,780,085,405 |
| Previous Close | 22.94 |
| Price Eps Current Year | -5.3473196 |
| Price Hint | 2 |
| Price To Book | -0.0012258418 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.826 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 24.19 |
| Regular Market Day Low | 22.765 |
| Regular Market Day Range | 22.765 - 24.19 |
| Regular Market Open | 23.0 |
| Regular Market Previous Close | 22.94 |
| Regular Market Price | 22.94 |
| Regular Market Time | 1,780,084,801 |
| Regular Market Volume | 497,133 |
| Return On Assets | -0.22731 |
| Return On Equity | -0.36896 |
| Sand P52 Week Change | 0.2794361 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 129,565,608 |
| Shares Percent Shares Out | 0.020499999 |
| Shares Short | 1,954,558 |
| Short Name | Kailera Therapeutics, Inc. |
| Short Percent Of Float | 0.020499999 |
| Short Ratio | 2.32 |
| Source Interval | 15 |
| State | MA |
| Symbol | KLRA |
| Target High Price | 57.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 42.6 |
| Target Median Price | 42.0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 22.92069 |
| Two Hundred Day Average Change | 0.019309998 |
| Two Hundred Day Average Change Percent | 0.00084247015 |
| Type Disp | Equity |
| Volume | 497,133 |
| Website | https://www.kailera.com |
| Zip | 2,451 |